One of the questions hovering around the US biosimilars space is what kind of patent settlements will prompt antitrust enforcement actions by the Federal Trade Commission and others. While the answer remains to be seen, stakeholders are preparing for government scrutiny.
A panel of two lawyers and an economist discussed the antitrust landscape for biosimilars during an Oct. 4 webinar hosted...






